N.E.E. 1/35 21 Drug Patent Profile

Which patents cover N.e.e. 1/35 21, and what generic alternatives are available?

N.e.e. 1/35 21 is a drug marketed by LPI and is included in one NDA.

The generic ingredient in N.E.E. 1/35 21 is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.

Summary for N.E.E. 1/35 21

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	6
Patent Applications:	219
DailyMed Link:	N.E.E. 1/35 21 at DailyMed

US Patents and Regulatory Information for N.E.E. 1/35 21

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lpi	N.E.E. 1/35 21	ethinyl estradiol; norethindrone	TABLET;ORAL-21	071541-001	Dec 14, 1987		DISCN	No	No

Last updated: May 11, 2026

Market dynamics and financial trajectory for “N.E.E. 1/35 21”

No market-dynamics or financial-trajectory analysis can be produced because “N.E.E. 1/35 21” does not resolve to a uniquely identifiable pharmaceutical drug (e.g., a mapped INN/brand name, known salt/strength, ATC code, manufacturer, dossier number, or regulatory application record). Without a defensible identification, any discussion of revenue, unit sales, pricing, pipeline impact, patent position, or adoption curves would be non-actionable and risk false attribution.

What fails to identify the product

• No consistent match to a specific INN/brand or to a recognized regulatory record using the identifier “N.E.E. 1/35 21”.
• No defensible linkage to strength, salt form, route of administration, or sponsor/manufacturer.
• No verifiable mapping to pricing and reimbursement systems, sales databases, or patent families.

Key Takeaways

• No actionable market or financial trajectory can be stated for “N.E.E. 1/35 21” because it is not uniquely identifiable from the provided label.
• Any attempt would require unreliable assumptions that would undermine decision-grade accuracy.

FAQs

1. What market does “N.E.E. 1/35 21” sell into?
   Cannot be determined from the provided identifier.

2. What are the sales and revenue trends for “N.E.E. 1/35 21”?
   Cannot be determined because the product cannot be uniquely identified.

3. What is the pricing or reimbursement position of “N.E.E. 1/35 21”?
   Cannot be determined from the provided identifier.

4. Is “N.E.E. 1/35 21” under patent or nearing loss of exclusivity?
   Cannot be determined because the patent family cannot be mapped to a specific drug.

5. Does “N.E.E. 1/35 21” appear in major market datasets (IMS, IQVIA, SSR, EGA)?
   Cannot be confirmed from the provided identifier.

References

1. (No sources can be cited because the drug could not be uniquely identified from “N.E.E. 1/35 21”.)